ORMP
ORAMED PHARMACEUTICALS INC.Company Information
- Company Name
- ORAMED PHARMACEUTICALS INC.
- CIK
- CIK0001176309
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ORMP: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ORMP
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-07-01
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 210,360
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 14,818,321
- Shares outstanding
- 41,040,479
- Ownership
- 36.11%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- 19.29%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 15 | 13 | 46 | 52 | 16 | 75 | 54 | 42 | 85 | 19 | 9 | 5 | ||||||
| Deposits Assets Current | - | 11 | 11 | 4 | 23 | 27 | 55 | 43 | 2 | 80 | 95 | 120 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | 57 | 66 | 78 | 58 | - | ||||||
| Marketable Securities Current | 1 | 5 | 5 | 5 | 2 | 4 | 3 | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 53 | 68 | 133 | 136 | 99 | 131 | 143 | 143 | 153 | 177 | 163 | 176 | ||||||
| Equity Securities Fv Ni | 35 | 37 | 64 | 74 | 58 | 26 | 29 | - | - | - | 58 | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 2 | 3 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | ||||||
| Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Marketable Securities Noncurrent | 22 | 18 | 8 | - | - | 4 | - | 1 | 2 | 2 | 2 | 3 | ||||||
| Investment Owned At Fair Value | 87 | 51 | 10 | 11 | 9 | 5 | 7 | - | - | 20 | 51 | - | ||||||
Assets Noncurrent | ||||||||||||||||||
| Assets Noncurrent | 316 | 201 | 98 | 84 | 63 | 16 | 12 | 22 | 31 | 27 | 58 | 55 | ||||||
| Equity Method Investments | - | - | - | - | - | 1 | - | - | - | - | - | - | ||||||
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | 199 | 102 | 72 | 65 | 44 | - | - | - | - | - | - | - | ||||||
| Equity Method Investments Fair Value Disclosure | 0 | 0 | 1 | 1 | 3 | - | - | - | - | - | - | - | ||||||
| Real Estate Investments | - | - | 2 | 2 | 2 | - | - | - | - | - | - | - | ||||||
| Other Long Term Investments | 2 | 2 | - | - | - | - | - | - | - | - | - | - | ||||||
| Equity Securities F V N I Noncurrent | 4 | 4 | 4 | 4 | 4 | 4 | 4 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Assets | 370 | 269 | 231 | 220 | 162 | 148 | 155 | 165 | 184 | 204 | 221 | 231 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 9 | 9 | 6 | 5 | 2 | 5 | 5 | 5 | 3 | 1 | 2 | 3 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 11 | 11 | 19 | 6 | 4 | 5 | 6 | 5 | 4 | 34 | 53 | 78 | ||||||
| Short Term Borrowings | - | - | - | - | - | - | - | - | - | 32 | 51 | 75 | ||||||
| Notes Payable Current | - | - | 1 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | - | ||||||
| Deferred Income Current | - | - | 1 | 1 | 1 | - | - | - | - | - | - | - | ||||||
| Contract With Customer Liability Current | 2 | 1 | - | - | - | - | - | - | - | - | - | - | ||||||
| Dividends Payable Current | 0 | 0 | 11 | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Revenue Noncurrent | - | - | - | - | - | - | - | - | - | 4 | 4 | 4 | ||||||
| Taxes Payable Current And Noncurrent | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | - | ||||||
| Contract With Customer Liability Noncurrent | - | - | 2 | 2 | 2 | 2 | 4 | 4 | 4 | - | 4 | - | ||||||
| Employee Related Liabilities Current And Noncurrent | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Liabilities Noncurrent | 41 | 20 | 12 | 12 | 4 | 2 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Liability For Uncertain Tax Positions Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Deferred Income Noncurrent | - | - | 1 | 1 | 2 | - | - | - | - | - | - | - | ||||||
| Deferred Income | 1 | 2 | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | - | 0 | - | ||||||
| Dividends Payable Current And Noncurrent | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Deferred Income Tax Liabilities Net | 40 | 18 | 8 | 8 | - | - | - | - | - | - | - | - | ||||||
Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 324 | 323 | 323 | 325 | 325 | 325 | 322 | 322 | 323 | 322 | 321 | 320 | ||||||
| Retained Earnings Accumulated Deficit | -7 | -85 | -123 | -123 | -171 | -184 | -177 | -166 | -147 | -156 | -158 | -171 | ||||||
| Stockholders Equity | 317 | 238 | 200 | 202 | 154 | 141 | 146 | 156 | 177 | 167 | 164 | 149 | ||||||
| Minority Interest | - | - | - | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Liabilities And Stockholders Equity | 370 | 269 | 231 | 220 | 162 | 148 | 155 | 165 | 184 | 204 | 221 | 231 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | ||||||
| Common Stock Shares Issued | 41 | 41 | 39 | 41 | 41 | 41 | 40 | 40 | 41 | 41 | 40 | 40 | ||||||
| Shares Outstanding | 41 | 41 | 39 | 41 | 41 | 41 | 40 | 40 | 41 | 41 | 40 | 40 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialORAMED PHARMACEUTICALS INC. (ORMP) — SEC Financial Statements & Analysis
ORAMED PHARMACEUTICALS INC. (ORMP) is a pharmaceutical preparations company, incorporated in DE. ORAMED PHARMACEUTICALS INC. trades on Nasdaq as: ORMP. ORAMED PHARMACEUTICALS INC. (ORMP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, ORAMED PHARMACEUTICALS INC. carries a market cap of $197.40M, a P/E ratio of 3.08x, a P/B ratio of 0.62x, a P/S ratio of 98.70x, an enterprise value of $182.16M, and an EV/EBITDA multiple of -12.17x. On profitability, it posts an operating margin of -754.40%, a net margin of 3200.80%, a Return on Equity (ROE) of 27.18%, a Return on Assets (ROA) of 24.10%, and a Return on Invested Capital (ROIC) of 0.00%. Per share, it reports EPS of $1.56, diluted EPS of $1.51, free cash flow per share of $-0.22, and a dividend per share of $0.25. Over the trailing year, it posted revenue growth of 0.00% year-over-year, net income growth of -435.87% year-over-year, and EPS growth of -441.62% year-over-year. On the balance sheet, it maintains a current ratio of 4.98x, a quick ratio of 4.77x, working capital of $42.68M, a debt-to-equity ratio of 0.16x, a debt ratio of 0.14, an interest coverage ratio of -14.98x, free cash flow of $-9.15M (TTM), and net debt of $-15.24M. Figures sourced from SEC EDGAR.
- Market Cap
- $197.40M
- P/E TTM
- 3.08x
- EPS TTM
- $1.56
- P/B TTM
- 0.62x
- ROE TTM
- 27.18%
- ROA TTM
- 24.10%
- Debt To Equity
- 0.16x
- Free Cash Flow TTM
- $-9.15M
- Net Revenue TTM Growth 1Y
- 0.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ORAMED PHARMACEUTICALS INC. in?
ORAMED PHARMACEUTICALS INC. (ORMP) operates in the Pharmaceutical Preparations industry.
What exchange does ORMP trade on?
ORAMED PHARMACEUTICALS INC. (ORMP) trades on the Nasdaq.
Where is ORAMED PHARMACEUTICALS INC. incorporated?
ORAMED PHARMACEUTICALS INC. is incorporated in DE.
When was ORAMED PHARMACEUTICALS INC. (ORMP)'s most recent SEC filing?
ORAMED PHARMACEUTICALS INC. (ORMP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is ORMP's market cap?
ORAMED PHARMACEUTICALS INC. (ORMP) has a market capitalization of $197.40M as of 2026-06-30.
What is ORMP's P/E ratio?
ORAMED PHARMACEUTICALS INC. (ORMP)'s trailing twelve month P/E ratio is 3.08x as of 2026-06-30.
What is ORMP's EPS (earnings per share)?
ORAMED PHARMACEUTICALS INC. (ORMP)'s trailing twelve month EPS is $1.56 as of 2026-06-30.
What is ORMP's ROE (return on equity)?
ORAMED PHARMACEUTICALS INC. (ORMP)'s trailing twelve month Return on Equity (ROE) is 27.18% as of 2026-06-30.
What is ORMP's ROA (return on assets)?
ORAMED PHARMACEUTICALS INC. (ORMP)'s trailing twelve month Return on Assets (ROA) is 24.10% as of 2026-06-30.
What is ORMP's ROIC (return on invested capital)?
ORAMED PHARMACEUTICALS INC. (ORMP)'s trailing twelve month Return on Invested Capital (ROIC) is 0.00% as of 2026-06-30.
What is ORMP's EV/EBITDA?
ORAMED PHARMACEUTICALS INC. (ORMP)'s trailing twelve month EV/EBITDA is -12.17x as of 2026-06-30.